ArticleAntimicrobial agents and chemotherapy2004
Mechanism of increased fluconazole resistance in Candida glabrata during prophylaxis.
Article in Antimicrobial agents and chemotherapy, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 96 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
96 citing papers in PubMed.
- Article
- Review
- Leveraging synthetic genetic array screening to identify therapeutic targets and inhibitors for combatting azole resistance inMicrobiology spectrum · 2025Article
- Emergence of invasive candidiasis with multipleFrontiers in microbiology · 2025Article
- Hospitalized COVID-19 Patients with Urinary Tract Infection in Iran:Antibiotics (Basel, Switzerland) · 2024Article
- Invasive candidiasis.Nature reviews. Disease primers · 2024Review
- Evaluation of Antifungal Selective Toxicity UsingJournal of fungi (Basel, Switzerland) · 2023Article
- Characterizing Candida glabrata Pdr1, a Hyperactive Transcription Factor Involved in Azole Resistance.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Article
- Poly(methyl methacrylate) with Oleic Acid as an EfficientMaterials (Basel, Switzerland) · 2022Article
- Impact of the COVID-19 Pandemic on the Clinical Profile of Candidemia and the Incidence of Fungemia Due to Fluconazole-ResistantJournal of fungi (Basel, Switzerland) · 2022Article
- Augmenting Azoles with Drug Synergy to Expand the Antifungal Toolbox.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Epidemiology of Fungal Colonization in Children Treated at the Department of Oncology and Hematology: Single-Center Experience.International journal of environmental research and public health · 2022Article
- Prevalence of Antifungal Resistance, Genetic Basis of Acquired Azole and Echinocandin Resistance, and Genotyping of Candida krusei Recovered from an International Collection.Antimicrobial agents and chemotherapy · 2022Article
- What 'Omics can tell us about antifungal adaptation.FEMS yeast research · 2022Review
- Fungicide effects on human fungal pathogens: Cross-resistance to medical drugs and beyond.PLoS pathogens · 2021Review
- Recent Trends in the Epidemiology of Fungal Infections.Infectious disease clinics of North America · 2021Review
- First Report of Candidemia Clonal Outbreak Caused by Emerging Fluconazole-Resistant Candida parapsilosis Isolates Harboring Y132F and/or Y132F+K143R in Turkey.Antimicrobial agents and chemotherapy · 2020Article
- Plant-Derived Substances in the Fight Against Infections Caused byInternational journal of molecular sciences · 2020Review
- Candida glabrata Transcription Factor Rpn4 Mediates Fluconazole Resistance through Regulation of Ergosterol Biosynthesis and Plasma Membrane Permeability.Antimicrobial agents and chemotherapy · 2020Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Candida glabrata can become resistant to fluconazole, causing persistent colonization and invasive infection during prolonged exposure to the drug. To determine the mechanism of resistance in this setting, weekly oropharyngeal cultures for C. glabrata were obtained over a 2-year period from hematopoietic stem cell transplant recipients who were receiving fluconazole prophylaxis. In 20 patients from whom at least two isolates of the same karyotype were obtained more than two weeks apart, fluconazole MICs doubled every 31 days on average. The mechanism of fluconazole resistance in isolates from the 14 of the 20 patients studied in whom MICs changed at least fourfold was studied. Cellular resistance was accompanied by increased drug efflux as measured by decreased accumulation of fluconazole and rhodamine 6G and increased abundance of transcripts from two drug transporters, CgCDR1 and PDH1. The rapidity and regularity of the rising resistance indicated that C. glabrata is able to upregulate drug efflux without losing the ability to maintain colonization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.